As Alzheimer’s Space Heats Up, Biopharma Leans In to Holistic Treatment
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, Otsuka and Lundbeck are renewing a decades-old search for symptomatic treatments, including in high-profile drugs like Cobenfy.
As Alzheimer’s Space Heats Up, Biopharma Leans In to Holistic Treatment Read More »
